Publications by authors named "O Imventarza"
Avoidance of steroids in pediatric liver transplantation may reduce toxicity and morbidity. The aim of this study was to analyze the feasibility of a steroid-free tacrolimus-basiliximab immunosuppression scheme, the risk factors associated with steroid requirement, and safety parameters. Patients who underwent liver transplantation for biliary atresia between 2011 and 2019 were included and followed for 6 months after transplantation.
View Article and Find Full Text PDFArticle Synopsis
- A study aimed to understand how tacrolimus is absorbed in pediatric liver transplant patients who cannot take the medication orally, particularly focusing on those who are sedated or on mechanical ventilation.
- Researchers collected data from 26 children who underwent liver transplants and analyzed it using a sophisticated modeling software, revealing that tacrolimus behaves differently based on sedation status.
- The findings suggest that the model successfully describes the medication's absorption and could improve dosing strategies post-transplant once validated further.
Article Synopsis
- Scientists wanted to create a clear definition for what "Textbook Outcome in Liver Surgery" (TOLS) means, which shows the best possible results after liver surgery.
- They used a method called the Delphi process, where expert liver surgeons answered surveys, and they agreed on the definition only if 80% of them agreed on it.
- The final definition includes things like no serious incidents during surgery, no major problems after surgery, and a good recovery without re-hospitalization.
Background: It has long been debated whether cava anastomosis should be performed with the piggyback technique or cava replacement, with or without veno-venous bypass (VVB), with or without temporary portocaval shunt (PCS) in the setting of liver transplantation.
Objectives: To identify whether different cava anastomotic techniques and other maneuvers benefit the recipient regarding short-term outcomes and to provide international expert panel recommendations.
Data Sources: Ovid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.
Although rituximab is widely used off-label for complex pediatric diseases, safety reports are limited. We aimed to report evidence of its use in clinical practice, to describe the incidence of adverse drug reactions (ADR) to rituximab biosimilar Novex and innovator, and to identify risk factors for the development of ADR in a real-life follow-up cohort of pediatric patients with complex diseases. We conducted a prospective, longitudinal, observational, single-centre study in patients that received rituximab for any complex disease, and as part of an intensive pharmacovigilance program.
View Article and Find Full Text PDF